Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase
使用 T 型钙通道和可溶性环氧化物水解酶的活性 IND 双重抑制剂开发治疗酒精使用障碍的新型药物
基本信息
- 批准号:10815882
- 负责人:
- 金额:$ 48.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-25 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:Absence of pain sensationAddressAlcohol consumptionAlcoholsAmendmentAmericanAnalgesicsAnimal ModelAnti-Inflammatory AgentsAnxietyAreaBehaviorBiological AssayBiological AvailabilityBrainCanis familiarisCardiacCardiac MyocytesCardiotoxicityCellsChronicClinicalClinical TrialsCollaborationsDarknessDataDepressed moodDevelopmentDiseaseDisease modelDisulfiramDrug DesignDrug KineticsDrug TargetingDrug usageElectrophysiology (science)Emergency department visitEnzymesEpoxide hydrolaseEthanolEvaluationExhibitsFDA approvedFOS geneFatty AcidsFutureHabenulaHalf-LifeHealthHumanHyperalgesiaHypersensitivityInflammationInflammation MediatorsInvestigationInvestigational DrugsInvestigational New Drug ApplicationIon ChannelLateralLeadLegal patentLigand BindingMechanicsMedicalMental DepressionMicrogliaMood DisordersMusNaltrexoneNeuronsOpiate AddictionOralOrganPainPain DisorderPenetrationPeripheralPharmaceutical PreparationsPharmacology StudyPhasePhase I Clinical TrialsPublic HealthRattusRewardsRodentSafetySelf AdministrationSeriesSmall Business Innovation Research GrantSubstance Use DisorderSucroseSurveysSymptomsT-Type Calcium ChannelsTestingTherapeuticToxic effectToxicologyTranslatingUniversitiesWithdrawalacamprosateagedalcohol seeking behavioralcohol use disorderanimal painanxiety-like behaviorbinge drinkingchronic alcohol ingestionchronic neuropathic painchronic painclinical developmentcomorbiditycomparison controldensitydeter alcohol useevidence baseglial activationhealthy volunteerinflammatory paininhibitorinnovationlead optimizationnegative affectnerve injuryneuralneuroinflammationnon-opioid analgesicnoveloverdose deathpain modelpainful neuropathypatch clamppharmacokinetics and pharmacodynamicspre-clinicalpreferencereceptorresponsereward circuitryscreeningside effectspared nervesuccess
项目摘要
7. SUMMARY
Alcohol use disorder (AUD) is the most prevalent substance use disorder worldwide and often co-occurs with
chronic pain, anxiety, depression, and opioid dependence. Unfortunately, currently available medications for
AUD have limited efficacy with unwanted side effects. To address this unmet medical need, we propose an SBIR
Phase I U43 project in response to PAR-22-102 "Investigational New Drug (IND)-enabling and Early-Stage
Development of Medications to Treat Alcohol Use Disorder and Alcohol-Associated Organ Damage." Our project
will focus on proof-of-concept studies of our active IND (157314), AFA-281, a novel dual inhibitor of T-type
calcium channels (Cav3) and soluble epoxide hydrolase (sEH), for AUD treatment. These proof-of-concept
studies would use well-established rodent AUD models and testing paradigms.
AfaSci discovered AFA-281 from a series of patented dual modulators of Cav3 channels and sEH as a non-
opioid analgesic. We completed lead identification through rational drug design and iterative screenings using
patch-clamp recordings and enzymatic assays. Lead optimization was conducted, including selectivity screening
on hERG and key cardiac ion channels, and CEREP proofing of 81 off-drug targets. These screenings together
with studies using human cardiomyocytes ex vitro demonstrated that AFA-281 has no cardiac safety concerns.
In pharmacokinetic and pharmacodynamic (PK/PD) studies, AFA-281 has shown excellent oral bioavailability,
acceptable t1/2, CNS penetration, broad analgesic effects on neuropathic and inflammatory pain, and good safety
margins. Recently, AFA-281's IND application was accepted by the FDA for a lead indication of neuropathic pain.
Our preliminary studies on AUD have demonstrated that AFA-281 is capable of decreasing alcohol intake, binge
drinking and preference, and suppressing alcohol-seeking behavior in rodents.
In this proposed SBIR Phase I U43 project, we will conduct preclinical proof-of-concept studies to investigate
AFA-281's effects on AUD, and its associated chronic pain and negative affective disorders, such as anxiety and
depression in rats via three Specific Aims. Aim 1 will evaluate PK/PD of AFA-281 in reducing alcohol consuming
and seeking behavior via operant self-administration. Aim 2 will investigate AFA-281's effects on hyperalgesia,
anxiety, and depression in rats withdrawn from chronic alcohol consumption. Aim 3 will explore the mechanism
of action of AFA-281 underlying its efficacy in AUD via assessing AFA-281’s modulation on alcohol-altered neural
activity indicated by c-Fos expression and brain neuroinflammation, and evaluation of Cav3 channel activity, and
cell excitability in the lateral habenula, a brain area implicated in AUD.
Success in our Phase I project would demonstrate that AFA-281 can reduce alcohol consumption and seeking
behavior, provide an evidence base to prepare for the transition to clinical proof-of-concept studies in the U44
SBIR project. Given the significant public health burden of AUD, developing a more effective and safe medication
accessible for treatment and prevention of AUD would have a considerable positive impact on public health.
7.总结
酒精使用障碍(AUD)是世界范围内最普遍的物质使用障碍,通常与
慢性疼痛、焦虑、抑郁和阿片依赖。不幸的是,目前可用的药物
AUD的疗效有限,有不良副作用。为了解决这一未得到满足的医疗需求,我们提出了SBIR
I期U43项目响应PAR-22-102“研究性新药(IND)-使能和早期阶段
治疗酒精使用障碍和酒精相关器官损伤的药物开发。“我们的项目
将专注于我们的活性IND(157314)AFA-281的概念验证研究,AFA-281是一种新型T型双重抑制剂
钙通道(Cav 3)和可溶性环氧化物水解酶(sEH),用于AUD治疗。这些概念验证
研究将使用完善的啮齿动物AUD模型和测试范例。
AfaSci从Cav 3通道和sEH的一系列专利双调节剂中发现了AFA-281,
阿片类镇痛药我们通过合理的药物设计和迭代筛选,
膜片钳记录和酶测定。进行了先导物优化,包括选择性筛选
对hERG和关键心脏离子通道的影响,以及对81个停药靶点的CEREP验证。这些放映在一起
体外使用人心肌细胞的研究证明AFA-281没有心脏安全性问题。
在药代动力学和药效学(PK/PD)研究中,AFA-281显示出优异的口服生物利用度,
可接受的t1/2、CNS渗透性、对神经性和炎性疼痛的广泛镇痛作用和良好的安全性
利润率最近,AFA-281的IND申请被FDA接受,用于神经性疼痛的主要适应症。
我们对AUD的初步研究表明,AFA-281能够减少酒精摄入量,
饮酒和偏好,以及抑制啮齿动物的酒精寻求行为。
在这个拟议的SBIR I期U43项目中,我们将进行临床前概念验证研究,以调查
AFA-281对AUD及其相关慢性疼痛和负性情感障碍(如焦虑和抑郁)的影响
通过三个具体目标对大鼠进行抑郁症治疗。目的1将评估AFA-281在减少饮酒方面的PK/PD
并通过自我管理寻求行为。目的2研究AFA-281对痛觉过敏的影响,
焦虑和抑郁的大鼠从慢性酒精消费中撤出。目标3将探讨机制
通过评估AFA-281对酒精改变的神经细胞的调节,
通过c-Fos表达和脑神经炎症指示的活性,以及Cav 3通道活性的评价,以及
外侧缰核的细胞兴奋性,这是一个与AUD有关的大脑区域。
在我们的第一阶段项目的成功将证明,AFA-281可以减少酒精消费和寻求
行为,提供证据基础,为在U44中过渡到临床概念验证研究做准备
SBIR项目。鉴于AUD的重大公共卫生负担,开发更有效和安全的药物
可获得的治疗和预防AUD将对公共卫生产生相当大的积极影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xinmin Simon Xie其他文献
Xinmin Simon Xie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xinmin Simon Xie', 18)}}的其他基金
Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain
Cav3通道和可溶性环氧化物水解酶的单分子双重抑制剂治疗神经性疼痛的IND临床I期试验
- 批准号:
10760089 - 财政年份:2023
- 资助金额:
$ 48.39万 - 项目类别:
Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase
使用 Cav3 通道和可溶性环氧化物水解酶的 IND 双重抑制剂开发可卡因使用障碍的新型治疗方法
- 批准号:
10786151 - 财政年份:2023
- 资助金额:
$ 48.39万 - 项目类别:
Development of selective Cav3 channel blockers for treatment of neuropathic pain
开发用于治疗神经性疼痛的选择性 Cav3 通道阻滞剂
- 批准号:
8779431 - 财政年份:2014
- 资助金额:
$ 48.39万 - 项目类别:
Development of selective Cav3 channel blockers for treatment of neuropathic pain
开发用于治疗神经性疼痛的选择性 Cav3 通道阻滞剂
- 批准号:
9136310 - 财政年份:2014
- 资助金额:
$ 48.39万 - 项目类别:
Development of selective Cav3 channel blockers for treatment of neuropathic pain
开发用于治疗神经性疼痛的选择性 Cav3 通道阻滞剂
- 批准号:
9143175 - 财政年份:2014
- 资助金额:
$ 48.39万 - 项目类别:
Development of patented tricyclic pyrones molecules for the treatment of Alzheimer’s Disease
开发用于治疗阿尔茨海默病的专利三环吡喃酮分子
- 批准号:
9442675 - 财政年份:2013
- 资助金额:
$ 48.39万 - 项目类别:
Development of patented tricyclic pyrones molecules for the treatment of Alzheimer’s Disease
开发用于治疗阿尔茨海默病的专利三环吡喃酮分子
- 批准号:
9744038 - 财政年份:2013
- 资助金额:
$ 48.39万 - 项目类别:
Development of Novel Tricyclic Pyrone Drugs for Treatment of Alzheimer Disease
治疗阿尔茨海默病的新型三环吡喃酮药物的开发
- 批准号:
8516617 - 财政年份:2013
- 资助金额:
$ 48.39万 - 项目类别:
Development of Novel Tricyclic Pyrone Drugs for Treatment of Alzheimer Disease
治疗阿尔茨海默病的新型三环吡喃酮药物的开发
- 批准号:
8681291 - 财政年份:2013
- 资助金额:
$ 48.39万 - 项目类别:
Development of patented tricyclic pyrones molecules for the treatment of Alzheimer’s Disease
开发用于治疗阿尔茨海默病的专利三环吡喃酮分子
- 批准号:
9348491 - 财政年份:2013
- 资助金额:
$ 48.39万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 48.39万 - 项目类别:
Research Grant